Navigation Links
Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008
Date:7/21/2008

TORONTO, July 21 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc. (Lorus), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today reported financial results for the three and twelve months ended May 31, 2008. Unless specified otherwise, all amounts are in Canadian dollars.

2008 HIGHLIGHTS

- Initiation of GLP toxicology studies for Lorus' lead anticancer small

molecule drug LOR-253. The toxicology studies, currently underway,

are designed to support the filing of an Investigational New Drug

(IND) application with the U.S. FDA for LOR-253 to initiate a Phase I

clinical study in cancer indications. Lorus intends to submit an IND

for LOR-253 by the Q4/2008 or 1Q/2009, following successful

completion of the toxicology program in the third quarter of 2008

calendar year.

- Announced completion of a proof-of-concept clinical trial in Acute

Myeloid Leukemia (AML), and expansion of its LOR-2040 development

program in this indication, with initiation of a more advanced

Phase II clinical trial. The proof-of-concept study generated

encouraging results demonstrating safety and appropriate dosing of

the combination regimen. Notably, promising clinical responses in

patients under 60 years of age were obtained which included complete

responses in 35% of the 23 patients and significant cytoreduction of

leukemic blasts in two others. Moreover, the clinical responses

correlated with downregulation of R2, the cellular target of LOR-

2040, and were further supported by demonstration of intracellular

LOR-2040 in circulating and bone marrow leukemic cells.

- Signed an exclusive multinational license agreement with Zor

Pharmaceuticals LLC ("ZOR") formed as a subs
'/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Lorus Therapeutics Receives $600 Thousand From Escrow Account
2. Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program
3. Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
4. Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions
5. Lorus initiates development program exploring novel route of administration for LOR-2040
6. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
7. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
8. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
9. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
10. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
11. Northwest Biotherapeutics to Present at Next Generation Vaccine Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014  Alternative Energy & Environmental ... has signed a letter of intent to acquire ... and patented a nanotechnology-based development platform used to ... enable rapid on-site collection and testing to identify ... issues in an immediate, non-invasive and cost-effective manner. ...
(Date:12/22/2014)... , Dec. 22, 2014  ( www.competitivehealth.com ) ... an online medical bill review and advocacy service, has ... the FREE WellCard Savings discount health services marketplace. ... that was more than they expected to pay. As ... health care costs, WellCard Savings is pleased to offer ...
(Date:12/22/2014)... Illinois (PRWEB) December 22, 2014 ITRA ... tenants and occupiers of commercial real estate, has further ... new offices in Perth and Brisbane, Western Australia, reports ... of directors. , ITRA Global / ACORPP (Australian ... totally independent consultancy company providing property services to a ...
(Date:12/19/2014)... 19, 2014 Bioject Medical Technologies ... manufacturer of needle-free injection technology, today announced that ... Therapeutics, Inc. (“ITI”) for ITI to use the ... LAMP™ vaccine platform. , In the agreement, ... license to the Biojector®-2000 that triggers based on ...
Breaking Biology Technology:ALNE Announces Intention To Acquire BioTechPharma 2WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3
... Andreas Krebs Named President of Europe/Middle East/Africa and ... Wyeth,Pharmaceuticals, a division of Wyeth (NYSE: WYE ... to President - Europe/Middle East/Africa,and Canada, effective immediately. ... Joseph M. Mahady, President - Wyeth Pharmaceuticals, and ...
... Sciences, LLC, a,member company of W. R. Berkley ... Prime is a uniquely innovative primary,liability policy designed ... companies of all sizes., LS Prime features ... and premises operations coverages. Included,with this broad protection ...
... Collagen ... Properties of Radiesse, SAN MATEO, Calif., June 26 ... of five studies in the,June 2008 issue of the Journal ... Dermatologic Surgery. The five,published clinical and preclinical reports were:, ...
Cached Biology Technology:Berkley Life Sciences Introduces LS Prime: A Revolutionary New Primary Liability Policy for the Life Science Industry 2Radiesse(R) Dermal Filler Featured Prominently in Journal of Dermatologic Surgery Special Issue on Fillers 2Radiesse(R) Dermal Filler Featured Prominently in Journal of Dermatologic Surgery Special Issue on Fillers 3Radiesse(R) Dermal Filler Featured Prominently in Journal of Dermatologic Surgery Special Issue on Fillers 4Radiesse(R) Dermal Filler Featured Prominently in Journal of Dermatologic Surgery Special Issue on Fillers 5Radiesse(R) Dermal Filler Featured Prominently in Journal of Dermatologic Surgery Special Issue on Fillers 6
(Date:12/4/2014)... , Dec. 3, 2014  Crossmatch™, a leading ... that its DigitalPersona ® Pro Enterprise software ... been deployed throughout First Bank branch locations in ... South Carolina and Virginia. First Bank, a ... Southern Pines, North Carolina , selected the ...
(Date:12/3/2014)... 2014 As part of our commitment to ... pleased to announce the release of a new reader ... the workforce data that they need. The ... by existing readers. Many such devices have serious shortcomings ... technology. Older models force users to navigate numerous complicated ...
(Date:11/21/2014)... YORK , Nov. 19, 2014  Earlier this ... at New York College, and one of the most ... biosensor signals that are transmitted from Smartphones to third ... were Smartphones and has one of the earliest known ... discussing its usage in the military, child care, elder ...
Breaking Biology News(10 mins):First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Inception Technologies to Release New Biometric Reader 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
... for developing complex protein drugs from bacteria has been ... bacterium E. coli , researchers from the University,s ... increase the efficiency of the cells producing specifically modified ... The modification is present in over two-thirds of human ...
... Ore. A new study finds that utilities aren,t ... are needed to make energy efficiency as attractive as ... issue of Environmental Law , examines key differences ... Scott, an assistant professor at Oregon State University, outlines ...
... portable, and wearable air pollution sensor, developed under the ... the Health Datapalooza in Washington, D.C. The grand prize ... The challenge was held by the National Institutes of ... Information Technology (ONC) of the U.S. Department of Health ...
Cached Biology News:New screening technique paves the way for protein drugs from bacteria 2Study finds disincentives to energy efficiency can be fixed 2NIH, ONC, and EPA award $100,000 to winner of health and technology challenge 2
... Recognizes K+ Cl- Cotransporter-1 ... no significant sequence homology ... CCC.,SPECIES REACTIVITIES: The immunogen ... in human, mouse, porcine ...
...
Anti-G-alpha-i 1 G-Protein Host: mouse monoclonal Species Reactivity: human, mouse, rat Applications: WB Storage: 4C...
oligophrenin-1 (H-100)...
Biology Products: